AFMD: Kapitalisasi marang bathi resik kanthi nimbang wutah Affimed Therapeutics

The development of immunotherapy via NK-cell activation is stimulating capital inflows, which validates the calculated PEG ratio for Affimed (AFMD). This parameter has stabilized at 0.00, reflecting the current market valuation. Growth prospects are based on the robotization of antibody screening using AI and strict adherence to European biosafety standards for the disposal of laboratory materials.

Affimed (AFMD) creates high added value through its proprietary bispecific antibody technology, which is reflected in the stock's valuation via the PEG ratio. This indicator compares the price-to-earnings multiple with the earnings growth rate: a value below one signals that the asset is undervalued relative to business dynamics, allowing investors to identify the potential for a sharp surge in share prices while maintaining a fundamental margin of safety.